Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04861259 · ClinicalTrials.gov registry record · Phase 3
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
A Phase 3 study of Atypical Hemolytic-Uremic Syndrome, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 3
- Development phase
- 83
- Enrollment target
- 20
- Study locations
NCT04861259: Active Phase 3 study of Atypical Hemolytic-Uremic Syndrome, sponsored by Hoffmann-La Roche.
NCT04861259 is a Phase 3 study of Atypical Hemolytic-Uremic Syndrome that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 83 participants, below the 1,025-participant average among 3 other Atypical Hemolytic-Uremic Syndrome trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04861259, a Phase 3 study of Atypical Hemolytic-Uremic Syndrome, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 83 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study aims to evaluate the efficacy and safety of crovalimab in adult and adolescent participants with aHUS.
Conditions Studied
Interventions
- DRUG Crovalimab
Study Locations (20)
Other
- UZ Leuven Gasthuisberg - Leuven
- Peking University First Hospital - Beijing
- Hopital Lapeyronie - Montpellier
- Hôpital Arnaud de Villeneuve - Montpellier
- Hôpital Robert Debré - Paris
- Hopital Tenon - Paris
- Klinik II für Nephrologie, Rheumatologie, Diabetologie und Allgemeine Innere Medizin - Cologne
- Universitätsklinikum Essen - Essen
- Klinik für Nephrologie des Universitätsklinikum Essen - Essen
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- The Ohio State University Wexner Medical Center - Columbus
São Paulo
- UPECLIN Hospital das Clinicas da Faculdade de Medicina de Botucatu - Botucatu
- Hospital das Clinicas - FMUSP - São Paulo
California
- Univ of CA San Francisco - San Francisco
Colorado
- Children's Hospital Colorado - Aurora
Georgia
- Emory Children's Center - Atlanta
Missouri
- Washington University - St Louis
Texas
- UT Health Science Center - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2021-10-22 |
| Est. Completion | 2029-08-20 |
| Phase | Phase 3 |
What the registry record for NCT04861259 still lists
NCT04861259 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 83 participants, a relatively small participant target, below the 1,025-participant average among 3 other Atypical Hemolytic-Uremic Syndrome trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Atypical Hemolytic-Uremic Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Crovalimab is the first listed.
NCT04861259 names 20 study sites across 10 states, led by Other, Ohio, São Paulo.
Frequently Asked Questions
What is clinical trial NCT04861259 about?
NCT04861259 is a clinical study titled "A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)". This study aims to evaluate the efficacy and safety of crovalimab in adult and adolescent participants with aHUS.
What is the current status of trial NCT04861259?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 83 participants. The study started on 2021-10-22. Estimated completion is 2029-08-20.
What conditions does trial NCT04861259 study?
This clinical trial studies the following conditions: Atypical Hemolytic-Uremic Syndrome.
What interventions are being tested in trial NCT04861259?
The interventions under investigation include: Crovalimab (DRUG).
Who is sponsoring clinical trial NCT04861259?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04861259 being conducted?
This trial has 20 study locations across California, Colorado, Georgia, Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atypical Hemolytic-Uremic Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy
ACTIVE NOT RECRUITING · Phase 3
-
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
ACTIVE NOT RECRUITING · Phase 3
-
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02974647 · 83 participants · Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- NCT03919292 · 83 participants · Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- NCT04626674 · 83 participants · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- NCT05277168 · 83 participants · Phase 1
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI